Clinical burden of disease and demographics in older adults hospitalised with RSV infection in England: A retrospective cohort study
Preprint
Abstract
Introduction: Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults ≥75-years, 65-74-years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults <75-years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilisation (HCRU), and mortality in adults hospitalised with RSV in England. Methods: Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults ≥60-years hospitalised with RSV between October 2014-March 2019 were included. RSV episodes defined as 90-days post diagnosis. Case definitions were created using diagnosis codes related to confirmed RSV (RSV-specific) or acute lower respiratory tract infection where other causative pathogens were excluded (RSV-possible). All-cause HCRU (hospitalisations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60-74 and ≥75-years), case definitions (RSV-specific, RSV-possible) and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). Results: A total of 97,712 hospitalised episodes in those aged ≥60-years were included in the analysis, where 785 (0.8%) were RSV-specific cases (n=338 aged 60-74-years, n=447 aged ≥75-years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those ≥75-years was 10.00 (6.00-22.00) days which was equivalent to or lower than each comorbidity sub-group in those aged 60-74-years, with longest LoS in those immunocompromised (11.50 [7.00-26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85%-22.34%) compared to those ≥75-years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those ≥75-years (all-cause: 19.3%; RSV-related: 10.3%). Conclusion: HCRU within RSV episodes in those aged 60-74-years across comorbidity profiles was equal to or greater compared to those aged ≥75-years. These findings highlight the need to prioritise consideration of comorbidity groups that could benefit from RSV vaccination. Key summary points: Why carry out this study?: • There is growing evidence on the burden of disease of RSV, however there is still a question around whether everyone at risk of severe outcomes are covered by the UK vaccination programme. • There is a paucity in evidence on the clinical burden of RSV in adults <75-years, especially in those with comorbidities including cardiovascular risk factors. Granular HCRU and morality outcomes are required to inform policy decisions on RSV vaccination strategies in these groups. • This study aimed to quantify the clinical burden of RSV in adults ≥60-years in England, stratified by comorbidity profile and descriptively compare to those previously eligible for the RSV-vaccine programme in England (aged ≥75-years, and in those in adult care homes). What was learned from the study?: • The study found that the clinical burden of RSV in secondary care in adults aged 60-74-years across all comorbidities stratifications, is equivalent to or exceeds the burden of those aged ≥75-years.Keywords
Funding Information
- Pfizer UK
This publication has 27 references indexed in Scilit:
- Burden of respiratory syncytial virus infection in older adults hospitalised in England during 2023/24Journal of Infection, 2025
- Burden and severity of respiratory syncytial virus infection in adults with cardiovascular diseases: A systematic literature reviewProgress in Cardiovascular Diseases, 2025
- Severe respiratory syncytial virus infection in older adults – burden, clinical outcomes and implications for careRespiratory Medicine and Research, 2025
- Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims DatabasePharmacoEconomics - Open, 2025
- Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature ReviewCurrent Allergy and Asthma Reports, 2025
- Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patientsJournal of Infection, 2024
- Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT–PCRInfectious Diseases and Therapy, 2023
- RSV‐associated hospitalization in adults in the USA: A retrospective chart review investigating burden, management strategies, and outcomesHealth Science Reports, 2022
- Characteristics and Outcomes of Patients in the ICU With Respiratory Syncytial Virus Compared With Those With Influenza InfectionChest, 2022
- Decision-making process, outcome, and 1-year quality of life of octogenarians referred for intensive care unit admissionIntensive Care Medicine, 2006